Context Therapeutics Inc

Market Cap

$256M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.75+$0.20 (+12.90%)

Jun 5, 2026

52W High $3.3652W Low $0.56

Company Details

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to ...

CEO

—

IPO Date

Oct 20, 2021

Website

www.contexttherapeutics.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$40M

EPS (Diluted)

Free Cash Flow

-$33M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 6, 2026

FY 2025

Mar 23, 2026

Q4 2025

Mar 23, 2026

Q3 2025

Nov 5, 2025

Q2 2025

Aug 6, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee